Vaxcyte

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxcyte reports robust Q4 performance and eyes vaccine market growth

Vaxcyte's Q4 performance highlighted strong financials, promising pipeline programs, and strategic market positioning.
The company faces challenges in pediatric efficacy translation, differentiation, and operational scalability.
Opportunities lie in expanding manufacturing, leveraging unique vaccine approaches, and addressing critical medical needs.

Vaxcyte excels in 2023 with strong PCV progress and financial growth

Vaxcyte's strong performance in 2023, with progress in key PCV candidates and financial strength, positions them well in the competitive vaccine market. Challenges include uncertainties in the competitive landscape and adapting to different vaccination schedules globally. Opportunities lie in upcoming milestones, global commercialization, and meeting the demand for broadly protective vaccines.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET.

Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference

FOSTER CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the third quarter ended September 30, 2020 and provided a business update.

Vaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will present at the Jefferies Virtual London Healthcare Conference on Tuesday November 17, 2020 at 12:35pm ET.

Vaxcyte to Present at Jefferies Virtual London Healthcare Conference

FOSTER CITY, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 11:00 a.m. ET.

Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference

FOSTER CITY, Calif., Aug.  12, 2020  (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Vaxcyte, Inc. (Nasdaq: PCVX), please note that in the first bullet under “Recent Highlights”, the date should be June 16, 2020, not June 16, 2010. The corrected release follows:

CORRECTION – Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.

Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update

Bio-Rad Laboratories

Forma Therapeutics Holdings

IMARA

Keros Therapeutics

Avidity Biosciences

Repare Therapeutics

SPDR S&P Biotech ETF

Zentalis Pharmaceuticals

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Biotech IPOs are booming -- but it's not all about Covid-19

FOSTER CITY, Calif., June  16, 2020  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of its initial public offering of 17,968,750 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 2,343,750 additional shares of common stock, at a public offering price of $16.00 per share. All of the shares were offered by Vaxcyte. The aggregate gross proceeds from the offering were $287.5 million, before deducting underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “PCVX” on June 12, 2020.

Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Shares of Vaxcyte Inc. soared 22% in their trading debut Friday, after the company's IPO priced at the top end of its price range, and was upsized to 15.6 million shares from earlier plans to sell just 14 million.

Vaccine maker Vaxcyte's shares soar 22% in trading debut

Vaxcyte Inc.  priced its initial public offering late Thursday at $16 a share, the top end of its price range, and upzied the deal to 15.6 million shares from earlier plans to sell just 14 million.

Vaccine maker Vaxcyte upsizes IPO and prices at top end of range

News for Vaxcyte Stock (PCVX)